|
|
|
|
|
|
The latest infectious diseases news from News Medical
|
|
|
|
|
|
|
|
|
|
|
|
From D614G to Omicron, ACROBiosystems are continually making efforts
From D614G to Omicron, the emergence of new variants continuously changed the fight against SARS-CoV-2. In 2021, with highly contagious, Delta and Omicron successively became the dominant variant around the world. COVID-19 vaccines are effective at preventing infection, serious illness, and death. Until the end of 2021, approximately 60% of people around the world have finished at least one dose. However, the emergence of breakthrough infection cases suggested the challenge to the effectiveness of the current vaccine against SARS-CoV-2 variants. ACROBiosystems is dedicated to aiding the global COVID-19 response and will keep watching the emerging SARS-CoV-2 variants.
|
|
|
|
|
| The most viewed Infectious Diseases news stories of 2021 were... |
|
|
|
|
Two mouthwashes disrupt COVID-19 virus under laboratory conditions
Researchers at Rutgers School of Dental Medicine have found evidence that two types of mouthwash disrupt the COVID-19 virus under laboratory conditions, preventing it from replicating in a human cell. The study, found that Listerine and the prescription mouthwash Chlorhexidine disrupted the virus within seconds after being diluted to concentrations that would mimic actual use.
|
|
New data from CDC on effectiveness of Pfizer and Moderna COVID-19 vaccines
Researchers conducted a study demonstrating the real-world effectiveness of the Pfizer-BioNTech and Moderna COVID-19 vaccines at preventing infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The large prospective study found that full vaccination was 91% effective at preventing SARS-CoV-2 infection, while partial vaccination was 81% effective.
|
|
|
|
| Fighting against SARS-CoV-2 infection |
|
|
|
ACRO’s effort: To support COVID-19 vaccine R&D with key reagents
ACROBiosystems is dedicated to supporting the global COVID-19 response. In 2021, they have built the most abundant SARS-CoV-2 recombinant antigen library with high purity and bioactivity and have developed a collection of binding and neutralizing antibodies that include the mutant-specific and broad-spectrum types. To facilitate current vaccine evaluation and new vaccine development, ACRO also developed a series of S protein pseudovirus with high sensitivity and luminescence, involving WT, Delta and Omicron. With high experience in technical services, neutralizing antibody detection services by pseudovirus can be offered now for their customers. Their products and services have consistently demonstrated excellence in quality and have been incorporated into the manufacturing and quality control systems of multiple vaccine companies.
|
|
|
|
|
| The most viewed Infectious Diseases articles of 2021 were... |
|
|
|
|
The Importance of Global COVID-19 Vaccination
COVID-19 vaccination is offering a way to end the COVID-19 pandemic if a response is coordinated globally.
|
|
What Does COVID-19 do to the Lungs?
Understanding what SARS-CoV-2 does to lung cells will enable better treatments for severe COVID-19.
|
|
|
|
| Achievement in the wars against SARS-CoV-2 |
|
|
|
Where do we go from here: A reflection of COVID-19
Since Jan 2020, SARS-CoV-2 launched a global pandemic that remains circulated today. Vaccination, as the cornerstone to prevent and control the spread of infectious diseases, has achieved unimaginable results in these two years. Until the end of 2021, except for 23 vaccines in use, there are now 137 COVID-19 vaccine candidates undergoing clinical trials and 194 candidates in pre-clinical development. Although there are still continuous SARS-CoV-2 variants and many black boxes about the virus, we should still be proud of our achievement and be confident in the fight against the virus. A reflection of COVID-19, including the achievement and unknown so far, was shared in the FREE eBook, following some possible solutions to research and vaccine development.
|
|
|
|
|
| More Infectious Diseases stories from 2021... |
|
|
|
|
Does SARS-CoV-2 natural infection immunity better protect against the Delta variant than vaccination?
A new study from Israel suggests immunity gained after recovering from a previous COVID-19 infection is more protective against the new Delta variant than vaccine-induced immunity. Natural immunity was estimated to be about 13 times stronger than having two doses of the Pfizer-BioNTech vaccine.
|
|
Intensity and duration of SARS-CoV-2 immunity may depend on ABO blood group
A team of scientists from Canada and Spain recently evaluated the durability of antigen-specific immune responses in COVID-19 recovered individuals. They have also identified potential host factors associated with robust and long-lasting anti-SARS-CoV-2 immunity. The study is currently available on the bioRxiv* preprint server.
|
|
|
|
__637770621813510973_multisizecolor_0_custom.jpg)
